Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q2FY26 results Revenue from Operations: Rs 567.5 crore against Rs 525.8 crore during Q2FY25, change 7.9%. EBITDA: Rs 64.0 crore against Rs 48.0 crore during Q2FY25, change 33.3%. EBITDA Margin: 11.1% for Q2FY26. PAT: Rs 30.0 crore against Rs 19.2 crore during Q2FY25, change 56.7%. PAT Margin: 5.2% for Q2FY26. Vikas Gupta, Joint Managing Director, said: “Q2FY26 reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% YoY. Importantly, EBITDA margin improved to 11.1% from 9.1%, driven by better operating leverage and cost efficiencies. Profit After Tax increased 56.7% YoY with PAT margin expanding to 5.2% from 3.6%, underscoring the strength of our integrated model. However, PAT was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs. Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs. We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.” Result PDF
